Not Yet Recruiting Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD) NCT07326592 Conditions Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +10 more Locations Not specified View Trial Details
Completed Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency NCT00261833 Conditions Alpha1-Proteinase Inhibitor Deficiency, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, +9 more Locations Study Site — Denver, Colorado, United States Study Site — Miami, Florida, United States Study Site — Hershey, Pennsylvania, United States Study Site — Tyler, Texas, United States View all 28 locations View more locations Show fewer locations Loading locations... View Trial Details
